URGN (UroGen Pharma Ltd.) Stock Market Reviews

crown

search

Read and share opinions on URGN (UroGen Pharma Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

URGN

UroGen Pharma Ltd.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report
Nov 9, 2025
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Nov 6, 2025
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
Nov 6, 2025
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Nov 6, 2025
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
Nov 4, 2025
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Oct 30, 2025
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Oct 29, 2025
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
Oct 27, 2025
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
Oct 2, 2025
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 8, 2025
UroGen Pharma to Present at Upcoming Investor Conferences
Aug 21, 2025
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 10, 2025
UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...
Aug 8, 2025
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
Aug 7, 2025

Reviews